<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002221" GROUP_ID="EYES" ID="575799071908412786" MERGED_FROM="" MODIFIED="2011-11-05 14:15:51 +0100" MODIFIED_BY="Anupa Shah" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.2">
<COVER_SHEET MODIFIED="2011-11-05 14:15:51 +0100" MODIFIED_BY="Anupa Shah">
<TITLE>Interventions for involutional lower lid entropion</TITLE>
<CONTACT MODIFIED="2011-11-05 14:15:51 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="11191" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kostas</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Boboridis</LAST_NAME><EMAIL_1>kosbob@otenet.gr</EMAIL_1><MOBILE_PHONE>+30 6944183700</MOBILE_PHONE><ADDRESS><ORGANISATION>Aristotle University of Thessaloniki</ORGANISATION><ADDRESS_1>Pavlou Mela 16</ADDRESS_1><CITY>54622 Thessaloniki</CITY><COUNTRY CODE="GR">Greece</COUNTRY><PHONE_1>+30 2310 260066</PHONE_1><FAX_1>+30 2310 252966</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-11-05 14:15:51 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="11191" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kostas</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Boboridis</LAST_NAME><EMAIL_1>kosbob@otenet.gr</EMAIL_1><MOBILE_PHONE>+30 6944183700</MOBILE_PHONE><ADDRESS><ORGANISATION>Aristotle University of Thessaloniki</ORGANISATION><ADDRESS_1>Pavlou Mela 16</ADDRESS_1><CITY>54622 Thessaloniki</CITY><COUNTRY CODE="GR">Greece</COUNTRY><PHONE_1>+30 2310 260066</PHONE_1><FAX_1>+30 2310 252966</FAX_1></ADDRESS></PERSON><PERSON ID="9831" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Catey</FIRST_NAME><LAST_NAME>Bunce</LAST_NAME><POSITION>Senior Medical Statistician</POSITION><EMAIL_1>c.bunce@ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Research and Development Department</DEPARTMENT><ORGANISATION>Moorfields Eye Hospital NHS Foundation Trust</ORGANISATION><ADDRESS_1>City Road</ADDRESS_1><CITY>London</CITY><ZIP>EC1V 2PD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7566 2820</PHONE_1><FAX_1>+44 20 7608 6925</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-11-04 12:05:41 +0000" MODIFIED_BY="Anupa Shah">
<UP_TO_DATE>
<DATE DAY="2" MONTH="11" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="11" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="8" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2011-11-04 16:43:51 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-11-04 13:19:29 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="4" MONTH="11" YEAR="2011"/>
<DESCRIPTION>
<P>With the inclusion of a new trial, the conclusions for this review have been updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-11-04 16:43:51 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="11" YEAR="2011"/>
<DESCRIPTION>
<P>Issue 12, 2011: Updated searches yielded one new trial for inclusion (<LINK REF="STD-Scheepers-2010" TYPE="STUDY">Scheepers 2010</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-11-04 12:20:10 +0000" MODIFIED_BY="Anupa Shah">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-11-04 12:20:10 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="11" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="20" MONTH="11" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-11-04 16:47:59 +0000" MODIFIED_BY="Anupa Shah">
<INTERNAL_SOURCES MODIFIED="2011-11-04 16:47:59 +0000" MODIFIED_BY="Anupa Shah">
<SOURCE MODIFIED="2011-11-04 16:47:59 +0000" MODIFIED_BY="Anupa Shah">
<NAME>NIHR</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Catey Bunce acknowledges financial support from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-11-05 13:16:42 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-11-04 13:47:05 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-11-04 13:47:05 +0000" MODIFIED_BY="Anupa Shah">Interventions for treating an inward turning lower eyelid in the elderly</TITLE>
<SUMMARY_BODY MODIFIED="2011-11-04 13:42:41 +0000" MODIFIED_BY="[Empty name]">
<P>Entropion is the inward turning of the eyelid, causing rubbing of the eyelashes and eyelid skin against the surface of the eye. It is one of the commonest forms of eyelid problems in older people and it more frequently involves the lower eyelid. In the early stages not all people require treatment but eventually every movement of the eye or eyelid causes trauma to the corneal surface which may lead to infection and ulceration with visual impairment. Surgery in the form of horizontal and vertical eyelid tightening is needed when the condition is severe and causes trauma to the cornea. The review authors searched the medical literature and found a single trial that met the inclusion criteria of the review. Sixty-three participants with lower eyelid entropion were enrolled and randomised to either everting sutures alone or everting sutures and a lateral tarsal strip. Eight participants were lost to follow-up. The trial showed that the combination of horizontal and vertical eyelid tightening with everting sutures and lateral tarsal strip is highly efficient for entropion compared to vertical tightening with everting sutures alone. Further research is needed to provide more credible evidence for the comparison of surgical treatments to correct an inward turning eyelid.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-11-04 13:52:48 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Entropion is a condition in which the eyelid margin turns in against the eyeball. Involutional or senile entropion is one of the most common lower lid malpositions in the elderly. The interventions described and currently used for the treatment of this condition are surgical in nature, although non-surgical temporary medical treatment for the early stages of entropion has also been reported. The relative effectiveness of these interventions has not yet been resolved.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-11-04 13:51:19 +0000" MODIFIED_BY="[Empty name]">
<P>To examine the effect of interventions for involutional entropion and to assess whether any method is superior to any other.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-11-04 13:52:48 +0000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (<I>The Cochrane Library</I> 2011, Issue 10), MEDLINE (January 1950 to November 2011), EMBASE (January 1980 to November 2011), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>),ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov).">http://clinicaltrials.gov)</A> and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). There were no date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 2 November 2011. We also searched oculoplastic textbooks, conference proceedings from the European and American Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS, ASOPRS), European Ophthalmological Society (SOE), the Association for Recearch in Vision and Ophthalmology (ARVO) and American Academy of Ophthalmology (AAO) for the years 2000 to 2009 to identify relevant data. We attempted to contact researchers who are active in this field for information about further published or unpublished studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-10-01 08:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) with no restriction on date or language comparing two or more surgical methods for correction of involutional lower eyelid entropion in people older than 60 years of age with involutional lower lid entropion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-11-04 12:54:25 +0000" MODIFIED_BY="[Empty name]">
<P>Each review author independently assessed study abstracts identified from the electronic and manual searches. Author analysis was then compared and full papers for appropriate studies were obtained according to the inclusion criteria. Disagreements between the authors were resolved by discussion.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-11-04 13:41:24 +0000" MODIFIED_BY="[Empty name]">
<P>We identified one RCT which met our inclusion criteria and was included in this review. Sixty-three participants with primary involutional lower eyelid entropion were randomised to everting sutures alone or everting sutures with a lateral tarsal strip. Eight participants were lost to follow-up. The trial indicates that the combined procedure for horizontal and vertical eyelid tightening in the form of everting sutures and lateral tarsal strip is highly curative for involutional entropion compared to vertical tightening in the form of everting sutures alone. The superiority of the combined approach is also supported by many good quality uncontrolled studies on specific surgical procedures but these were not included in the analysis as they were not part of the inclusion criteria.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-11-04 13:18:22 +0000" MODIFIED_BY="[Empty name]">
<P>A single RCT showed that the combination of horizontal and vertical eyelid tightening with everting sutures and lateral tarsal strip is highly efficient for entropion compared to vertical tightening with everting sutures alone. Retrospective case series studies also support the combined surgical repair but details from these studies on specific surgical techniques cannot be included in the analysis.</P>
<P>Evidence from a single RCT is unlikely to change clinical practice and thus it is still our view that there is a clear need for more randomised studies comparing two or more surgical techniques for entropion surgery addressing the recurrence and complications rate.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-11-04 16:42:12 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-11-04 13:50:28 +0000" MODIFIED_BY="Anupa Shah">
<CONDITION MODIFIED="2011-11-03 16:48:55 +0000" MODIFIED_BY="[Empty name]">
<P>Entropion is a condition in which the eyelid margin and eyelashes turn in towards the eyeball. It is divided into four main types according to the cause: congenital, involutional, spastic and cicatricial. Involutional or senile entropion is one of the most common lower lid malpositions in the elderly population and one of the most common treated in clinical practice (<LINK REF="REF-Levine-1998" TYPE="REFERENCE">Levine 1998</LINK>; <LINK REF="REF-Pereira-2010" TYPE="REFERENCE">Pereira 2010</LINK>).</P>
<P>The prevalence of involutional lower lid entropion has been reported to be 2.1% in the elderly population (1.9% in men and 2.4% in women) with no reported details for the frequency of its surgical management (<LINK REF="REF-Damasceno-2011a" TYPE="REFERENCE">Damasceno 2011a</LINK>). It is characterised by constant rubbing of the eyelid margin, eyelashes and skin against the ocular surface resulting in inflammation of the conjunctiva and corneal abrasions. This can result in secondary corneal thinning, vascularisation and scarring. Corneal ulceration and perforation may occur in chronic cases (<LINK REF="REF-Musch-1983" TYPE="REFERENCE">Musch 1983</LINK>; <LINK REF="REF-Tse-1992" TYPE="REFERENCE">Tse 1992</LINK>). Patients complain of a chronic foreign body sensation, redness, tearing and discharge.</P>
<P>The main aetiological factors of this condition are progressive senile changes in the following eyelid structures (<LINK REF="REF-Collin-1989" TYPE="REFERENCE">Collin 1989</LINK>; <LINK REF="REF-Damasceno-2011b" TYPE="REFERENCE">Damasceno 2011b</LINK>):<BR/>
</P>
<UL>
<LI>orbicularis muscle - changes allow the preseptal muscle to roll upwards over the pretarsal muscle;</LI>
<LI>lower lid retractors - laxity of the retractors allows the lower border of the tarsal plate to rotate outwards;</LI>
<LI>tarsal plate - loses its stiffness and inward buckling allows the upper border to invert more than the lower;</LI>
<LI>horizontal laxity - changes in the orbicularis muscle, canthal tendons and tarsus lead to horizontal laxity of the lower lid.</LI>
</UL>
<P>It has been suggested that the main causes for the inward turning of the lid are increased tone of the preseptal orbicularis muscle over the pretarsal part of the muscle; atrophy and shrinkage of the tarsal plate; and disinsertion of the lower lid retractors (<LINK REF="REF-Bashour-2000" TYPE="REFERENCE">Bashour 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-09-30 21:29:02 +0100" MODIFIED_BY="[Empty name]">
<P>Several surgical procedures addressing one or more of the aetiological factors have been developed over the years. <LINK REF="REF-Jones-1972" TYPE="REFERENCE">Jones 1972</LINK> reported that more than 80 procedures had been described, indicating that there was poor understanding of the disease process and low success rate in the available treatment modalities.</P>
<P>In current clinical practice, surgery for vertical lid shortening with or without horizontal shortening is considered the only long-term treatment for entropion. Vertical lid laxity can be corrected by indirectly reattaching the lower lid retractors as described by <LINK REF="REF-Wies-1954" TYPE="REFERENCE">Wies 1954</LINK>, or by directly reattaching the retractors as described by <LINK REF="REF-Jones-1963" TYPE="REFERENCE">Jones 1963</LINK>. Vertical shortening can be combined with horizontal shortening in the form of wedge excision or lateral canthal sling (<LINK REF="REF-Anderson-1979" TYPE="REFERENCE">Anderson 1979</LINK>; <LINK REF="REF-Tenzel-1969" TYPE="REFERENCE">Tenzel 1969</LINK>). Horizontal tightening of the orbicularis muscle, which also stabilises the retractors, has been described as a method for entropion repair (<LINK REF="REF-Wheeler-1938" TYPE="REFERENCE">Wheeler 1938</LINK>).</P>
<P>Non-surgical temporary treatment includes medical symptomatic support with antibiotic or lubricating ointment, taping the lid to the cheek and chemical denervation of the orbicularis muscle with botulinum toxin injections (<LINK REF="REF-Clarke-1988" TYPE="REFERENCE">Clarke 1988</LINK>; <LINK REF="REF-Neetens-1987" TYPE="REFERENCE">Neetens 1987</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2011-11-04 13:50:28 +0000" MODIFIED_BY="[Empty name]">
<P>Surgical management of entropion involves focusing on the involutional anatomical changes of the lower eyelid which are the main causative factors of the condition. Correction of horizontal and/or vertical eyelid laxity with any available surgical technique will stabilise the eyelid and prevent its inward turning and rubbing of the eyeball (<LINK REF="REF-Hintschich-2008" TYPE="REFERENCE">Hintschich 2008</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-09-30 21:45:37 +0100" MODIFIED_BY="[Empty name]">
<P>During the early stages of the disease there is only an intermittent inward turning of the lid and mild symptoms. Medical treatment may provide adequate comfort. With the progression of involutional changes the lid is constantly rubbing against the eyeball and surgical intervention may be required. It is not generally agreed when treatment should be given or which is the best surgical approach (<LINK REF="REF-Skorin-2003" TYPE="REFERENCE">Skorin 2003</LINK>).</P>
<P>This review will investigate the comparative effectiveness of various interventions for involutional lower lid entropion and will summarise potential complications related to surgery.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-11-04 13:51:28 +0000" MODIFIED_BY="[Empty name]">
<P>To review current published evidence for the effectiveness of surgical correction for involutional lower eyelid entropion and highlight information on possible complications</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-11-04 14:11:59 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-11-04 13:52:18 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-09-30 21:50:44 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) with no restriction on date or language that were identified by our search strategy. In the absence of RCTs we discussed well documented findings of non-randomised studies which were identified by the same search methods or were included as a selective summary.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We considered trials in which participants were people older than 60 years of age with involutional lower lid entropion, as defined by the investigator.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-11-04 12:22:00 +0000" MODIFIED_BY="[Empty name]">
<P>We included studies that compared one intervention for involutional lower lid entropion with another intervention.</P>
<P>Surgical techniques were divided into four groups:</P>
<OL>
<LI>those that indirectly addressed vertical lid laxity (inferior retractor dehiscence);</LI>
<LI>those that directly addressed vertical lid laxity;</LI>
<LI>those that directly addressed horizontal lid laxity;</LI>
<LI>combination of vertical and horizontal shortening.</LI>
</OL>
<P>We also included studies of botulinum toxin injection, medical symptomatic support and taping the lid to the cheek.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-11-04 13:52:18 +0000" MODIFIED_BY="[Empty name]">
<P>We divided the outcome measures into:</P>
<OL>
<LI>short-term (up to six months after intervention);</LI>
<LI>intermediate (six to 18 months);</LI>
<LI>long-term (more than 18 months).</LI>
</OL>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-11-04 13:52:18 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>successful surgery i.e. normal eye lid position at rest.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-11-04 12:22:32 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>recurrence;</LI>
<LI>adverse events and complications such as over-correction;</LI>
<LI>quality of life;</LI>
<LI>socioeconomic implications (cost of treatment, outpatient visits, days off work).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-11-04 13:53:19 +0000" MODIFIED_BY="Anupa Shah">
<ELECTRONIC_SEARCHES MODIFIED="2011-11-04 13:53:19 +0000" MODIFIED_BY="Anupa Shah">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2011, Issue 10, part of <I>The Cochrane Library</I>. <A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A> (accessed 2 November 2011), MEDLINE (January 1950 to November 2011), EMBASE (January 1980 to November 2011), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov).">http://clinicaltrials.gov)</A> and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 2 November 2011.</P>
<P>See: Appendices for details of search strategies for CENTRAL (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), <I>m</I>RCT (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>),ClinicalTrials.gov (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>) and the ICTRP (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>) .</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-09-30 22:02:43 +0100" MODIFIED_BY="Anupa Shah">
<P>We searched oculoplastic textbooks and bibliographies of relevant reports to find further trials. We contacted investigators and experts in the field, members of the ESOPRS and EUGOGO for details of other published and unpublished studies. We also searched conference proceedings from the European and American Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS, ASOPRS), European Ophthalmological Society (SOE), the Association for Recearch in Vision and Ophthalmology (ARVO) and American Academy of Ophthalmology (AAO) for the years 2000 to 2009 to identify relevant data.</P>
<P>For each identified RCT we included in the review, we manually searched the reference lists of the trials cited for additional information.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-11-04 14:11:59 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-11-04 14:06:58 +0000" MODIFIED_BY="Anupa Shah">
<P>Two authors independently screened the titles and abstracts obtained from the searches to determine which studies fulfilled the eligibility criteria. We excluded reports that did not meet the inclusion criteria and obtained full-text copies of reports referring to trials that possibly or definitely met the inclusion criteria. Two authors assessed the full-text copies and selected studies according to the inclusion criteria. The selected trials were further assessed for quality whereas excluded studies were listed in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' and reasons for exclusion documented. We resolved disagreements between the authors by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-11-04 12:10:20 +0000" MODIFIED_BY="Anupa Shah">
<P>Two authors independently extracted the following information from the identified trials and entered it in to Review Manager (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>):</P>
<P>Methods: inclusion and exclusion criteria, method of allocation, and other aspects of study design.<BR/>Details of participants: age, gender, setting, number in each group, comparability at baseline.<BR/>Details of interventions: technique, stage of the disease, comparison group.<BR/>Outcomes: primary and secondary outcomes, adverse effects.<BR/>Other information: funding.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-11-04 14:07:29 +0000" MODIFIED_BY="Anupa Shah">
<P>Two authors independently assessed the included studies for sources of systematic bias according to the guidelines in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved disagreements by discussion. We considered the following domains for risk of bias and assessed each one as low risk of bias), high risk of bias and unclear.</P>
<UL>
<LI>Sequence generation: looking at the method of randomisation in the allocation of the participants.</LI>
<LI>Allocation concealment.</LI>
<LI>Masking (blinding) of physicians and participants.</LI>
<LI>Incomplete outcome data: the completeness of outcome data for outcomes will be reported, including attrition and exclusions from analysis.</LI>
<LI>Selective outcome reporting.</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-11-04 14:07:59 +0000" MODIFIED_BY="[Empty name]">
<P>We sought guidance from Chapter 9 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). Our primary outcome measure (successful surgery) was dichotomous and so we used the odds ratio.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-11-04 14:08:26 +0000" MODIFIED_BY="[Empty name]">
<P>There were no unit of analysis issues. The only trial identified included one eye of each participant and this was reflected in the analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-09-30 22:19:26 +0100" MODIFIED_BY="[Empty name]">
<P>In case we were unable to extract all the required information from the included studies, we requested the missing data from the investigators. A period of four weeks was allowed for the authors to respond and if no response was provided after this period it was recorded as missing data and the review was conducted based on available information.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-11-04 14:09:31 +0000" MODIFIED_BY="[Empty name]">
<P>If additional trials are identified for inclusion in the future, heterogeneity will be assessed by careful review of the full-text papers. We normally anticipate some degree of heterogeneity to be present due to the clinical and methodological differences of the studies. If they appear similar methodologically we will assess consistency by examination of the I<SUP>2</SUP> statistic. We considered values of I<SUP>2</SUP> of 50% or greater to indicate substantial heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-11-04 14:10:04 +0000" MODIFIED_BY="[Empty name]">
<P>If in the future there are a sufficient number of trials (10 or more), we will use a funnel plot to assess evidence of publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-11-04 14:11:07 +0000" MODIFIED_BY="[Empty name]">
<P>For future updates, if there is no evidence of heterogeneity between trials we will combine the results in a meta-analysis using a random-effects model, unless the number of trials is three or less when a fixed-effects model is used. If substantial statistical or clinical heterogeneity is present we will not combine the studies in a meta-analysis but will present a descriptive overview of the outcome.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-11-04 14:11:59 +0000" MODIFIED_BY="[Empty name]">
<P>We did not intend to conduct subgroup analysis. For future updates, we will investigate heterogeneity by careful review of the study reports.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-09-30 22:31:12 +0100" MODIFIED_BY="[Empty name]">
<P>We plan to perform sensitivity analyses in order to determine the impact of excluded studies of lower methodological quality and unpublished studies.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-11-04 14:39:09 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-11-04 14:39:09 +0000" MODIFIED_BY="Anupa Shah">
<SEARCH_RESULTS MODIFIED="2011-11-04 14:39:09 +0000" MODIFIED_BY="Anupa Shah">
<P>The electronic searches yielded a total of 294 titles and abstracts and five reports of ongoing studies (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After de-duplication the Trials Search Co-ordinator scanned 267 records and discarded 156 records because they were not relevant to the scope of the review. We screened the title and abstracts of the remaining 111 references. We rejected 108 abstracts as not eligible for inclusion in the review. We obtained full-text copies of two reports for further examination, one was excluded from the review by both review authors on methodological grounds. One trial was included in the review. We found one ongoing study (<LINK REF="STD-NTR1653" TYPE="STUDY">NTR1653</LINK>) which is relevant to the review. This trial has been added to the '<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>' table and will be included in the review when data become available.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-09-30 23:17:47 +0100" MODIFIED_BY="[Empty name]">
<P>We included one RCT and details are given below. For additional information see the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
<P>
<LINK REF="STD-Scheepers-2010" TYPE="STUDY">Scheepers 2010</LINK> compared everting sutures (for vertical tightening) alone versus everting sutures with a lateral tarsal strip (for vertical and horizontal tightening) in the treatment of involutional lower lid entropion. The combined procedure was superior to the everting sutures alone as it produced no recurrences in the 18 month postoperative observation. From this paper we obtained data specific to the primary or secondary outcome measures.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-11-04 14:14:57 +0000" MODIFIED_BY="[Empty name]">
<P>We obtained the full-text copy of one of the reports for further examination and excluded it (see the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table). This paper (<LINK REF="STD-Altieri-2004" TYPE="STUDY">Altieri 2004</LINK>) stated that "the patients were randomly assigned into two treatment groups" but it was unclear whether a valid randomisation method was used. There was also an unspecific statement about the statistical significance of the comparison values and poor surgical justification of the findings. It was impossible to obtain further clarification from the authors or the journal. In addition the paper did not compare two distinct surgical procedures but it only evaluated the results of retractor plication performed with two different techniques. The two treatment comparisons were so similar that it could not be regarded truly as different surgical interventions as they both addressed vertical lid laxity by reattaching the inferior retractors to the tarsal plate.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-11-04 14:39:09 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias for <LINK REF="STD-Scheepers-2010" TYPE="STUDY">Scheepers 2010</LINK> by utilising the 'Risk of bias' assessment tool. This considers sequence generation, allocation concealment, masking of physicians and participants, incomplete outcome date, selective outcome reporting and other potential threats to validity. See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2011-11-04 14:17:24 +0000" MODIFIED_BY="[Empty name]">
<P>In the only included trial, eligible participants were randomised to everting sutures or everting sutures and lateral canthal strip by drawing an envelope from a box that contained one of the two randomisation assignments with half the participants randomised to each group. For participants with bilateral disease, only the first eyelid operated on was entered into the study.</P>
<P>No details of attempts to conceal allocation of intervention assignment were given posing a potential risk of bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-11-04 14:17:58 +0000" MODIFIED_BY="[Empty name]">
<P>In this trial there is no evidence that physicians and participants were masked (blinded) during the conduct and analysis of the study. This poses a potential risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-11-04 14:18:23 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome data were reported for 55 of the 63 participants who were enrolled in the study. This poses a potential risk of bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-09-30 23:34:19 +0100" MODIFIED_BY="[Empty name]">
<P>The trial was evaluated to be free of selective outcome reporting. The outcome measures listed in the methods were detailed in the results of the study.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-09-30 23:35:45 +0100" MODIFIED_BY="[Empty name]">
<P>There is no evidence that the identified study might be subject to other potential sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-11-04 14:18:51 +0000" MODIFIED_BY="[Empty name]">
<P>Due to the single included study, a meta-analysis could not be performed, therefore, the results are presented in a descriptive manner.</P>
<P>The non-RCTs identified by the same search method or included as selective summary are not robust enough to provide credible evidence to the current understanding of involutional lower lid entropion surgery and therefore their results will not be analysed.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-11-04 16:42:12 +0000" MODIFIED_BY="[Empty name]">
<P>The single RCT included in this review (<LINK REF="STD-Scheepers-2010" TYPE="STUDY">Scheepers 2010</LINK>) indicates that the combined procedure for horizontal and vertical eyelid tightening in the form of everting sutures and lateral tarsal strip is highly curative for involutional entropion compared to vertical tightening in the form of everting sutures alone. Although several suggestions for methodological improvements can be made (<LINK REF="REF-Boboridis-2011" TYPE="REFERENCE">Boboridis 2011</LINK>), this study provides the only available robust data to support evidence based guidelines for the management of lower lid entropion.</P>
<P>Before the publication of high level evidence, it was the physicians' understanding of the involutional anatomical and pathophysiological causative changes for the inward turning of the lower lid, along with uncontrolled, retrospective case series studies, that was formulating the current clinical practice with similar conclusions to the directions of surgical repair.</P>
<P>Vertical lid laxity corrected using the Wies procedure (<LINK REF="REF-Wies-1954" TYPE="REFERENCE">Wies 1954</LINK>) has reported overcorrections of up to 10% and a recurrence rate of 7/66 cases (11%) at a minimum of six months postoperative follow up (<LINK REF="REF-Wies-1955" TYPE="REFERENCE">Wies 1955</LINK>). When combined with horizontal shortening, recurrence rates of 0/29 cases at a minimum of six months follow up and 0/127 eyelids at an average follow up of 33 months have been reported (<LINK REF="REF-Carroll-1991" TYPE="REFERENCE">Carroll 1991</LINK>; <LINK REF="REF-Lance-1991" TYPE="REFERENCE">Lance 1991</LINK>). Some authors quote a 3.7% recurrence rate for the combined procedure (<LINK REF="REF-Collin-1978" TYPE="REFERENCE">Collin 1978</LINK>) and 1.6% for indirect retractor attachment with everting sutures combined with the tarsal strip procedure (<LINK REF="REF-Rougraff-2001" TYPE="REFERENCE">Rougraff 2001</LINK>). Correction of vertical lid laxity in the form of retractor plication with the Jones procedure (<LINK REF="REF-Jones-1963" TYPE="REFERENCE">Jones 1963</LINK>) has a reported recurrence rate of 2/12 patients (16.6%) (<LINK REF="REF-Dryden-1978" TYPE="REFERENCE">Dryden 1978</LINK>). The use of non-absorbable sutures for the reattachment of the retractors to the tarsal plate combined with partial myectomy of the preseptal orbicularis muscle has been reported to improve the recurrence rate from 14.7% to 7.1% (<LINK REF="STD-Altieri-2004" TYPE="STUDY">Altieri 2004</LINK>) which further decreases to 9/266 cases (3.3%) in combined procedures (<LINK REF="REF-van-den-Bosch-1998" TYPE="REFERENCE">van den Bosch 1998</LINK>). In a case series study, horizontal lid and orbicularis tightening has been shown to cure entropion in 36/45 cases (86%) (<LINK REF="REF-Olver-2000" TYPE="REFERENCE">Olver 2000</LINK>).</P>
<P>A retrospective case series suggested that Jones retractor plication is more likely to permanently cure entropion than the Wies procedure (<LINK REF="REF-Boboridis-2000" TYPE="REFERENCE">Boboridis 2000</LINK>). This study reported recurrence rates of 2/37 patients (5%) and 11/65 patients (17%) respectively at an average of 31 months of follow up. Recurrence occurred much earlier after the Wies procedure. Another retrospective study, from the same centre, suggested that successful outcome is more likely when surgery for entropion also addresses horizontal lid laxity, with a 2/180 patients (1%) recurrence rate compared with 29/133 patients (22%) when the lid is not shortened horizontally (<LINK REF="REF-Danks-1998" TYPE="REFERENCE">Danks 1998</LINK>).</P>
<P>These published reports from case series studies vary significantly in the information on follow-up length and methodology affecting the apparent success rate of each procedure (<LINK REF="REF-Glatt-1999" TYPE="REFERENCE">Glatt 1999</LINK>). Evidence from the available uncontrolled studies along with the only available RCT support the conclusion that direct vertical lid shortening combined with horizontal lid shortening gives the most favourable outcome in entropion surgery. Until more evidence in the form of RCTs is available we cannot make firm recommendations regarding specific surgical techniques and clinical practice.</P>
<SUMMARY_OF_RESULTS MODIFIED="2011-11-04 16:41:54 +0000" MODIFIED_BY="[Empty name]">
<P>The only RCT included (<LINK REF="STD-Scheepers-2010" TYPE="STUDY">Scheepers 2010</LINK>) provides evidence that the combined procedure for horizontal and vertical eyelid tightening in the form of everting sutures and lateral tarsal strip offers a higher success rate for involutional entropion compared to vertical tightening in the form of everting sutures alone. This trial was however judged to be at risk of of several important sources of bias. Until more trials become available we cannot make strong suggestions regarding specific surgical technique.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-11-04 14:53:04 +0000" MODIFIED_BY="[Empty name]">
<P>The literature on surgical management of involutional lower lid entropion consists predominantly of retrospective studies, cohort studies and case series which cannot be used for the establishment of reliable guidelines for the efficacy and safety of a specific procedure as a superior treatment intervention. One RCT was identified in this review which gives strong evidence for the direction of surgical intervention and the relative effectiveness of two surgical procedures.</P>
<P>The available evidence relates to the review question but it is insufficient to address all the review objectives as only two interventions are compared and numerous others are yet to be evaluated.</P>
<P>The target of surgical intervention for horizontal and vertical eyelid tightening is uniformly supported by the available RCT and most of the uncontrolled studies.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-11-04 16:42:12 +0000" MODIFIED_BY="[Empty name]">
<P>This review has identified a single RCT which has been found to be at risk of several sources of bias.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-11-04 16:41:33 +0000" MODIFIED_BY="[Empty name]">
<P>Despite extensive searching we identified only one study that met the inclusion criteria for this review. The available RCT was well conducted yet still at risk of several important sources of bias. Bias may distort systematic reviews and meta-analyses and encourages the use of questionable treatments (<LINK REF="REF-Dickersin-1992" TYPE="REFERENCE">Dickersin 1992</LINK>). This is not an issue for our review since we have not found adequate studies to perform meta-analysis and make recommendations. It should be noted that one of the authors of this review is an author of the published RCT and thus grading of the quality of evidence of this trial was left to the other author.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-11-04 14:32:17 +0000" MODIFIED_BY="[Empty name]">
<P>At present, <LINK REF="STD-Scheepers-2010" TYPE="STUDY">Scheepers 2010</LINK> provides the only robust data for lower lid entropion which cannot be formally compared with other studies. The general findings of this trial agree with the evidence found in most retrospective and case series studies (<LINK REF="REF-Boboridis-2000" TYPE="REFERENCE">Boboridis 2000</LINK>; <LINK REF="REF-Danks-1998" TYPE="REFERENCE">Danks 1998</LINK>), that horizontal and vertical tightening of the eyelid gives the most successful surgical outcome.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-10-04 09:37:36 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-10-04 09:37:14 +0100" MODIFIED_BY="[Empty name]">
<P>The only identified randomised controlled trial shows that the combined procedure for horizontal and vertical eyelid tightening in the form of everting sutures and lateral tarsal strip is more efficient compared to vertical tightening in the form of everting sutures alone. Uncontrolled studies also suggest that combination of horizontal and vertical lower lid shortening provides more favourable results compared to vertical shortening alone which is associated with higher recurrence and complications rates. These results from retrospective case series studies should be considered with caution.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-10-04 09:37:36 +0100" MODIFIED_BY="[Empty name]">
<P>This review highlights the need for more randomised controlled trials comparing interventions for lower lid entropion. However, data from retrospective studies may present ethical difficulties in randomising patients to certain less efficient procedures.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-11-04 16:48:33 +0000" MODIFIED_BY="Anupa Shah">
<P>We are grateful to Michael Wearne for peer review comments and to Anupa Shah for her assistance throughout the review process. The Cochrane Eyes and Vision Group editorial team developed the search strategies and undertook the electronic searches.</P>
<P>Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-11-05 13:16:42 +0000" MODIFIED_BY="Anupa Shah">
<P>Catey Bunce is an author on the <LINK REF="STD-Scheepers-2010" TYPE="STUDY">Scheepers 2010</LINK> trial included in this review.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-10-01 08:16:01 +0100" MODIFIED_BY="Anupa Shah">
<P>Please place the initials of each author that is assigned to the tasks below<BR/>Conceiving the review: KB<BR/>Designing the review: KB, CB<BR/>Co-ordinating the review: KB, CB<BR/>Data collection for the review<BR/>- Designing search strategies: Cochrane Eyes and Vision Group<BR/>- Undertaking searches: Cochrane Eyes and Vision Group<BR/>- Screening search results: KB, CB<BR/>- Organising retrieval of papers: KB, CB<BR/>- Screening retrieved papers against inclusion criteria: CB, KB<BR/>- Appraising quality of papers: CB, KB<BR/>- Extracting data from papers: CB, KB<BR/>- Writing to authors of papers for additional information: KB<BR/>- Providing additional data about papers: KB<BR/>- Obtaining and screening data on unpublished studies: KB, CB<BR/>Data management for the review<BR/>- Entering data into RevMan: CB, KB<BR/>Analysis of data: CB, KB<BR/>Interpretation of data<BR/>- Providing a methodological perspective: CB<BR/>- Providing a clinical perspective: KB<BR/>- Providing a policy perspective: KB, CB<BR/>- Providing a consumer perspective: KB, CB<BR/>Writing the review: KB<BR/>Providing general advice on the review: CB<BR/>Securing funding for the review: CB, KB<BR/>Performing previous work that was the foundation of the current study: KB</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-11-04 14:48:48 +0000" MODIFIED_BY="Anupa Shah">
<STUDIES MODIFIED="2011-11-03 16:37:54 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-11-03 16:37:54 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Scheepers-2010" MODIFIED="2011-11-03 16:37:54 +0000" MODIFIED_BY="[Empty name]" NAME="Scheepers 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-03 16:37:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Scheepers, Marius A&lt;br&gt;Singh, Ravi&lt;br&gt;Ng, James&lt;br&gt;Zuercher, Doris&lt;br&gt;Gibson, Andrew&lt;br&gt;Bunce, Catey&lt;br&gt;Fong, Ken&lt;br&gt;Michaelides, Michel&lt;br&gt;Olver, Jane&lt;br&gt;Comparative Study&lt;br&gt;Multicenter Study&lt;br&gt;Randomized Controlled Trial&lt;br&gt;United States&lt;br&gt;Ophthalmology&lt;br&gt;Ophthalmology. 2010 Feb;117(2):352-5. Epub 2009 Oct 28.&lt;/p&gt;" NOTES_MODIFIED="2011-11-03 16:37:54 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheepers MA, Singh R, Ng J, Zuercher D, Gibson A, Bunce C, et al</AU>
<TI>A randomized controlled trial comparing everting sutures with everting sutures and a lateral tarsal strip for involutional entropion</TI>
<SO>Ophthalmology</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2</NO>
<PG>352-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-09-30 21:27:53 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Altieri-2004" NAME="Altieri 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Not clear from the abstract whether there was any randomisation to groups.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altieri M, Kingston AE, Bertagno R, Altieri G</AU>
<TI>Modified retractor plication technique in lower lid entropion repair: a 4-year follow-up study</TI>
<SO>Canadian Journal of Ophthalmology</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>6</NO>
<PG>650-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2011-11-03 15:46:19 +0000" MODIFIED_BY=" Iris Gordon">
<STUDY DATA_SOURCE="UNPUB" ID="STD-NTR1653" MODIFIED="2011-11-03 15:46:19 +0000" MODIFIED_BY=" Iris Gordon" NAME="NTR1653" YEAR="1653">
<REFERENCE MODIFIED="2011-11-03 15:43:29 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="OTHER">
<AU>NTR1653</AU>
<TI>Lateral eyelid block excision versus lateral tarsal strip procedure to correct for horizontal eyelid laxity; a randomized controlled non-inferiority trial</TI>
<SO>apps.who.int/trialsearch/Trial.aspx?TrialID=NTR1653</SO>
<YR>(accessed 2 November 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-03 15:46:19 +0000" MODIFIED_BY=" Iris Gordon">
<IDENTIFIER MODIFIED="2011-11-03 15:46:19 +0000" MODIFIED_BY=" Iris Gordon" TYPE="OTHER" VALUE="NTR1653"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-11-04 14:48:48 +0000" MODIFIED_BY="Anupa Shah">
<ADDITIONAL_REFERENCES MODIFIED="2011-11-04 14:38:41 +0000" MODIFIED_BY="Anupa Shah">
<REFERENCE ID="REF-Anderson-1979" MODIFIED="2008-10-11 19:57:26 +0100" MODIFIED_BY="Anupa Shah" NAME="Anderson 1979" TYPE="JOURNAL_ARTICLE">
<AU>Anderson RL, Gordy DD</AU>
<TI>The tarsal strip procedure</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1979</YR>
<VL>97</VL>
<NO>11</NO>
<PG>2192-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bashour-2000" NAME="Bashour 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bashour M, Harvey J</AU>
<TI>Causes of involutional ectropion and entropion - age-related tarsal changes are the key</TI>
<SO>Ophthalmic Plastic and Reconstructive Surgery</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>2</NO>
<PG>131-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boboridis-2000" NAME="Boboridis 2000" TYPE="JOURNAL_ARTICLE">
<AU>Boboridis K, Bunce C, Rose GE</AU>
<TI>A comparative study of two procedures for repair of involutional lower lid entropion</TI>
<SO>Ophthalmology</SO>
<YR>2000</YR>
<VL>107</VL>
<NO>5</NO>
<PG>959-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boboridis-2011" MODIFIED="2011-11-03 16:44:26 +0000" MODIFIED_BY="[Empty name]" NAME="Boboridis 2011" TYPE="JOURNAL_ARTICLE">
<AU>Boboridis KG, Mikropoulos DG, Ziakas NG</AU>
<TI>Entropion</TI>
<SO>Ophthalmology</SO>
<YR>2011</YR>
<VL>118</VL>
<NO>1</NO>
<PG>225-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carroll-1991" MODIFIED="2008-10-11 19:57:29 +0100" MODIFIED_BY="Anupa Shah" NAME="Carroll 1991" TYPE="JOURNAL_ARTICLE">
<AU>Carroll RP, Allen SE</AU>
<TI>Combined procedure for repair of involutional entropion</TI>
<SO>Ophthalmic Plastic and Reconstructive Surgery</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>2</NO>
<PG>123-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1988" MODIFIED="2008-10-11 19:57:33 +0100" MODIFIED_BY="Anupa Shah" NAME="Clarke 1988" TYPE="JOURNAL_ARTICLE">
<AU>Clarke JR, Spalton DJ</AU>
<TI>Treatment of senile entropion with botulinum toxin</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1988</YR>
<VL>72</VL>
<NO>5</NO>
<PG>361-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collin-1978" MODIFIED="2008-10-11 19:57:35 +0100" MODIFIED_BY="Anupa Shah" NAME="Collin 1978" TYPE="JOURNAL_ARTICLE">
<AU>Collin JR, Rathbun JE</AU>
<TI>Involutional entropion. A review with evaluation of a procedure</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1978</YR>
<VL>96</VL>
<NO>6</NO>
<PG>1058-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collin-1989" MODIFIED="2008-10-11 19:57:41 +0100" MODIFIED_BY="Anupa Shah" NAME="Collin 1989" TYPE="BOOK">
<AU>Collin JRO</AU>
<SO>Entropion and trichiasis. A manual of systematic eyelid surgery</SO>
<YR>1989</YR>
<EN>2nd</EN>
<PB>Churchill Livingstone</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Damasceno-2011a" MODIFIED="2011-11-03 16:48:55 +0000" MODIFIED_BY="[Empty name]" NAME="Damasceno 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Damasceno RW, Osaki MH, Dantas PE, Belfort R Jr</AU>
<TI>Involutional entropion and ectropion of the lower eyelid: prevalence and associated risk factors in the elderly population</TI>
<SO>Ophthalmic Plastic and Reconstructive Surgery</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>5</NO>
<PG>317-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Damasceno-2011b" MODIFIED="2011-11-03 16:50:25 +0000" MODIFIED_BY="[Empty name]" NAME="Damasceno 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Damasceno RW, Osaki MH, Dantas PE, Belfort R Jr</AU>
<TI>Involutional ectropion and entropion: clinicopathologic correlation between horizontal eyelid laxity and eyelid extracellular matrix</TI>
<SO>Ophthalmic Plastic and Reconstructive Surgery</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>5</NO>
<PG>321-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Danks-1998" NAME="Danks 1998" TYPE="JOURNAL_ARTICLE">
<AU>Danks JJ, Rose GE</AU>
<TI>Involutional lower lid entropion: to shorten or not to shorten?</TI>
<SO>Ophthalmology</SO>
<YR>1998</YR>
<VL>105</VL>
<NO>11</NO>
<PG>2065-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2011-11-03 16:29:52 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1992" MODIFIED="2011-11-03 18:02:30 +0000" MODIFIED_BY="[Empty name]" NAME="Dickersin 1992" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Min YI, Meinert CL</AU>
<TI>Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards</TI>
<SO>JAMA</SO>
<YR>1992</YR>
<VL>267</VL>
<NO>3</NO>
<PG>374-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dryden-1978" NAME="Dryden 1978" TYPE="JOURNAL_ARTICLE">
<AU>Dryden RM, Leibsohn J, Wobig J</AU>
<TI>Senile entropion. Pathogenesis and treatment</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1978</YR>
<VL>96</VL>
<NO>10</NO>
<PG>1883-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J</AU>
<TI>How to identify randomized controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glatt-1999" NAME="Glatt 1999" TYPE="JOURNAL_ARTICLE">
<AU>Glatt HJ</AU>
<TI>Follow-up methods and the apparent success of entropion surgery</TI>
<SO>Ophthalmic Plastic and Reconstructive Surgery</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>6</NO>
<PG>396-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-11-03 16:27:27 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hintschich-2008" MODIFIED="2011-11-03 16:54:22 +0000" MODIFIED_BY="[Empty name]" NAME="Hintschich 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hintschich C</AU>
<TI>Correction of entropion and ectropion</TI>
<SO>Developments in Ophthalmology</SO>
<YR>2008</YR>
<VL>41</VL>
<PG>85-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1963" MODIFIED="2011-11-03 16:55:14 +0000" MODIFIED_BY=" Iris Gordon" NAME="Jones 1963" TYPE="JOURNAL_ARTICLE">
<AU>Jones LT, Reeh MJ, Tsujimura JK</AU>
<TI>Senile entropion</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1963</YR>
<VL>55</VL>
<PG>463-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1972" MODIFIED="2008-10-11 19:57:46 +0100" MODIFIED_BY="Anupa Shah" NAME="Jones 1972" TYPE="JOURNAL_ARTICLE">
<AU>Jones LT, Reeh MJ, Wobig JL</AU>
<TI>Senile entropion. A new concept for correction</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1972</YR>
<VL>74</VL>
<NO>2</NO>
<PG>327-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lance-1991" NAME="Lance 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lance SE, Wilkins RB</AU>
<TI>Involutional entropion: a retrospective analysis of the Wies procedure alone or combined with a horizontal shortening procedure</TI>
<SO>Ophthalmic Plastic and Reconstructive Surgery</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>4</NO>
<PG>273-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levine-1998" MODIFIED="2011-11-03 16:57:59 +0000" MODIFIED_BY=" Iris Gordon" NAME="Levine 1998" TYPE="BOOK_SECTION">
<AU>Levine RM, El-Toukhy E, Schaefer JA</AU>
<TI>Entropion</TI>
<SO>Smith's Ophthalmic Plastic and Reconstructive Surgery</SO>
<YR>1998</YR>
<PG>271-89</PG>
<EN>2nd</EN>
<ED>Nesi AF, Lisman DR, Levine RM</ED>
<PB>Mosby</PB>
<CY>St. Louis</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Musch-1983" MODIFIED="2011-10-01 00:21:16 +0100" MODIFIED_BY="Anupa Shah" NAME="Musch 1983" TYPE="JOURNAL_ARTICLE">
<AU>Musch DC, Sugar A, Meyer RF</AU>
<TI>Demographic and predisposing factors in corneal ulceration</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1983</YR>
<VL>101</VL>
<NO>10</NO>
<PG>1545-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neetens-1987" NAME="Neetens 1987" TYPE="JOURNAL_ARTICLE">
<AU>Neetens A, Rubbens MC, Smet H</AU>
<TI>Botulinum A-toxin treatment of spasmodic entropion of the lower eyelid</TI>
<SO>Bulletin de la Societe Belge d'Ophtalmologie</SO>
<YR>1987</YR>
<VL>224</VL>
<PG>105-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olver-2000" MODIFIED="2008-10-11 19:57:50 +0100" MODIFIED_BY="Anupa Shah" NAME="Olver 2000" TYPE="JOURNAL_ARTICLE">
<AU>Olver JM, Barnes JA</AU>
<TI>Effective small-incision surgery for involutional lower eyelid entropion</TI>
<SO>Ophthalmology</SO>
<YR>2000</YR>
<VL>107</VL>
<NO>11</NO>
<PG>1982-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pereira-2010" MODIFIED="2011-11-03 17:01:48 +0000" MODIFIED_BY="[Empty name]" NAME="Pereira 2010" TYPE="JOURNAL_ARTICLE">
<AU>Pereira MG, Rodrigues MA, Rodrigues SA</AU>
<TI>Eyelid entropion</TI>
<SO>Seminars in Ophthalmology</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>3</NO>
<PG>52-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-11-04 14:38:41 +0000" MODIFIED_BY=" Iris Gordon" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan).</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rougraff-2001" NAME="Rougraff 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rougraff P, Tse D, Johnson T, Feuer W</AU>
<TI>Involutional entropion repair with fornix sutures and lateral tarsal strip procedure</TI>
<SO>Ophthalmic Plastic and Reconstructive Surgery</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>4</NO>
<PG>281-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skorin-2003" MODIFIED="2011-11-03 18:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Skorin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Skorin L Jr</AU>
<TI>A review of entropion and its management</TI>
<SO>Contact Lens &amp; Anterior Eye</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>2</NO>
<PG>95-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tenzel-1969" MODIFIED="2008-10-11 19:57:54 +0100" MODIFIED_BY="Anupa Shah" NAME="Tenzel 1969" TYPE="JOURNAL_ARTICLE">
<AU>Tenzel RR</AU>
<TI>Treatment of lagophthalmos of the lower lid</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1969</YR>
<VL>81</VL>
<NO>3</NO>
<PG>366-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tse-1992" MODIFIED="2008-10-11 19:57:56 +0100" MODIFIED_BY="Anupa Shah" NAME="Tse 1992" TYPE="BOOK_SECTION">
<AU>Tse DT</AU>
<TI>Entropion</TI>
<SO>Color Atlas of Ophthalmic Surgery: Oculoplastic Surgery</SO>
<YR>1992</YR>
<PG>101-12</PG>
<ED>Tse DT</ED>
<PB>J. B. Lippincott Company</PB>
<CY>Pennsylvania</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-den-Bosch-1998" MODIFIED="2008-10-11 19:58:00 +0100" MODIFIED_BY="Anupa Shah" NAME="van den Bosch 1998" TYPE="JOURNAL_ARTICLE">
<AU>van den Bosch WA, Rosman M, Stijnen T</AU>
<TI>Involutional lower eyelid entropion: results of a combined approach</TI>
<SO>Ophthalmic Surgery and Lasers</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>7</NO>
<PG>581-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wheeler-1938" NAME="Wheeler 1938" TYPE="JOURNAL_ARTICLE">
<AU>Wheeler JM</AU>
<TI>Spastic entropion correction by orbicularis transplantation</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>1938</YR>
<VL>36</VL>
<PG>157-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wies-1954" NAME="Wies 1954" TYPE="JOURNAL_ARTICLE">
<AU>Wies FA</AU>
<TI>Surgical treatment of entropion</TI>
<SO>Journal of the International College of Surgeons</SO>
<YR>1954</YR>
<VL>21</VL>
<PG>758-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wies-1955" NAME="Wies 1955" TYPE="JOURNAL_ARTICLE">
<AU>Wies FA</AU>
<TI>Spastic entropion</TI>
<SO>Transactions of the American Academy of Ophthalmology and Otolaryngology</SO>
<YR>1955</YR>
<VL>59</VL>
<PG>503-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-11-04 14:48:48 +0000" MODIFIED_BY="Anupa Shah">
<REFERENCE ID="REF-Boboridis-2002" MODIFIED="2011-11-04 14:48:48 +0000" MODIFIED_BY="Anupa Shah" NAME="Boboridis 2002" TYPE="COCHRANE_REVIEW">
<AU>Boboridis KG, Bunce C</AU>
<TI>Interventions for involutional lower lid entropion</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-11-04 14:48:37 +0000" MODIFIED_BY="Anupa Shah">
<IDENTIFIER MODIFIED="2011-11-04 14:48:37 +0000" MODIFIED_BY="Anupa Shah" TYPE="DOI" VALUE="10.1002/14651858.CD002221"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-11-04 14:42:59 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-11-04 13:32:53 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-11-04 13:32:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scheepers-2010">
<CHAR_METHODS MODIFIED="2011-11-04 13:32:53 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial with a minimum follow up of 18 months. Only one eye per participant was included.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-01 08:45:02 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with involutional lower lid entropion requiring primary repair. 29 patients received everting sutures alone (group 1) and 26 had the combination of everting sutures and lateral tarsal sling (group 2).</P>
<P>Both groups were similar with respect to age, gender, and eye operated (gender Fisher&#8217;s exact test 1.000; laterality Fisher&#8217;s exact test 0.298).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-04 13:32:52 +0000" MODIFIED_BY="[Empty name]">
<P>Everting sutures plus lateral tarsal sling was compared with everting sutures alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 13:32:40 +0000" MODIFIED_BY="[Empty name]">
<P>Recurrence of entropion, overcorrection, potential complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-01 08:42:30 +0100" MODIFIED_BY="[Empty name]">
<P>Paper published in English</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-09-30 22:58:27 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-09-30 22:58:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Altieri-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 22:58:27 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear randomisation method. The two treatment comparisons are so similar techniques that it cannot be regarded truly as different surgical interventions.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-11-04 14:42:59 +0000" MODIFIED_BY=" Iris Gordon" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2011-11-04 14:42:59 +0000" MODIFIED_BY=" Iris Gordon" STUDY_ID="STD-NTR1653">
<CHAR_STUDY_NAME MODIFIED="2011-11-03 17:52:58 +0000" MODIFIED_BY=" Iris Gordon"/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS MODIFIED="2011-11-04 12:22:57 +0000" MODIFIED_BY=" Iris Gordon">
<P>Patients who have an eyelid condition for which a surgical procedure is planned that includes lateral horizontal eyelid tightening. The conditions include: ectropion, entropion, facial palsy, eyelid laxity due to ocular prosthesis wear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-04 12:22:59 +0000" MODIFIED_BY=" Iris Gordon">
<P>1. Lateral eyelid block excision.<BR/>2. Lateral tarsal strip procedure.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 14:42:59 +0000" MODIFIED_BY=" Iris Gordon">
<P>Surgical success at one year, defined as restoration of the lower eyelid position at the midline through the pupillary centre and at the lateral canthus, without in- or outward rotation of the lower eyelid margin.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-03 17:54:34 +0000" MODIFIED_BY=" Iris Gordon">
<P>1 March 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-04 12:23:12 +0000" MODIFIED_BY=" Iris Gordon">
<P>Dr. W.R. Bijlsma.University Medical Center Utrecht (UMCU), Oogziekenhuis Rotterdam (OZR)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-10-01 08:32:07 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-10-01 08:31:13 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-01 08:31:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scheepers-2010">
<DESCRIPTION>
<P>Clear details on the randomisation process were given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-10-01 08:30:49 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-01 08:30:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Scheepers-2010">
<DESCRIPTION>
<P>No evidence of concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-10-01 08:26:12 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-01 08:26:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scheepers-2010">
<DESCRIPTION>
<P>Incomplete outcome data was adequately addressed with the main outcome measures reported clearly for all participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-10-01 08:24:17 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-01 08:24:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scheepers-2010">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-10-01 08:25:21 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-01 08:25:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scheepers-2010">
<DESCRIPTION>
<P>No evidence of other potential source of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-10-01 08:28:38 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-01 08:28:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Scheepers-2010">
<DESCRIPTION>
<P>There is no evidence of participants masking (blinding) during the conduct and analysis of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-10-01 08:28:30 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-01 08:28:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Scheepers-2010">
<DESCRIPTION>
<P>There is no evidence of physicians masking during the conduct and analysis of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2011-11-04 14:39:09 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-11-04 14:39:09 +0000" MODIFIED_BY=" Iris Gordon" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Results from searching for studies for inclusion in the review.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-11-04 14:39:09 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///9BjlLGAAAcl0lEQVR42u1da3Ab13U+lLgvACS4S7IWo4wiiUr6Q39aJ1IsW1Rj0IqtNo3jTDP1+JEm+SHXSSedTDt5dSZ1/sSpErd13aSp6qlfsRtPOprYzkS2KSFOILkJ3dFMO6NMxuGrdETQI2KXlEguFguSva99gQAJggAEyufTA9i759x79uLDvXcX++0BQCAahjbQsRMQDYK1DfsA0TggvRBILwTSC4FAeiGQXgikFwKB9EJcM7RjF9QXFnZB6Eo90gvng3pjGTsDgd81BNILgUB6IZBeCKTXloHZdEdEg+iVIpBj2bK7rtWx7azQtp5YJ8IKjqny1isG0qjho1c6nZ6W+lvq2A6RqMqNTfb/1eboHWnJdtHG0a4Zk6MxXgTo1WSFfJ1TXapMXoZjCr2E68bluEsLFfkJW5UyzNyWFDVD90kJl1qqeooPDeSfGVPiJnNQbLJPpVWKMmC1dhEjN8FrTR6Tbb+eVFIVMaTYH1rOrbx2f2h3gy0rGmtbpj7g1+Wqg4FjTIkFMbB2NVYTQI8mq+S4MrKs9oC02I88asbaa68EcDVeiC+Q98tTCfKSUrNLZKP7hYLcTQuzZz/bN3VlkFl3Jpyh28i+EZfuS70yFRoEds05L+vMYTYJcKs2YQdlAAfkLL0y3G0VFForPHu2068Htk/BfLwwu0BGGTbOdL/Ay8Fr9wvnWNuv0rZneVysLvquS/ufRc9RVxx1lx8Da/fSCLdeMAuxRYDBRGFoHuBcAXnUaHrRtVdxFiA/A+YtZHvCoC/FESNHNpwbYTRPXnPGwKExQzvMPBQ3s98h+/rAJC/ufqMYmnAkGNBYLdS4ONpnB2UA2hivVWKeMG4MDPj1wIgB9gxot3hV3S3aHvfaXdpP2i7wtkUN7J3l0JZm8n4MozBS9GOgsIw+bm1r7CAlp2c/Md9fRB5VQL2UQqk02MYVMnrl9haXD6XpNv0nF9gL3SJvRSH7RwjVde9TnZfZdEi+/5LrW9IXXuhtpb0lNR8ojp/0jeSXy7jk9i4t8RiEs+KE2qUx0bY7ZkI+IW8IOYaChlBN5p6l4s1pyO1y2yb6eDweUBwDy3ojOkNT/or8fx/MXAmx1wS6tjlvljnZlxa+GbtKPlRyUkA+8CPcUlwWOM8LBc4z56DsaW5LPV/2jc4FLvfB5eDk8BxpeyXc7oDJ254PVym820Jh0qAHIhG7YP6ZOLWUf05n1IVp7T4S8FM4TDVh7TX7OFktnx2yu4OifD/00HlwH/SrpeZqxniRLMzUXtDjAG9ozPK8bVLuk7HsCc23bN+X1ViZzSux90I3WUCpLpyJBdXxeijOztiOz0q1tO1fXCSFNmtbyXo+pC6d1PWL/l6VMZLGoMG+X0YiToL2A/79/PXIbfwIXiKHfBFvO2nK0n7uqAlzR/pCdb5RUNvomsuRC7lS646jMpvJbDlPyDPRo1DL2eSOJ+nJf1J+MBgEZxf3kA883SXrV/mY6yi0jVyX9EjcNxL1sDg6WAztO6Bc2zJZSXUYvO33ej6krptIXT+1rxCSyTewCxDdsh29CDGn9vKaYp9hDSSOKoNzAIdl5FGD1171WsBVfRHEtmttxbz3+931jNr96LMGrr3Kr722g9Y6cU0tVWf31/+9feln/1ZrK3+XW3i9nlEns18PbeXb3vH0WtFCnYHPmKgr8Gbo0M3QFq5KG9W1CMAbchBILwTSC4FAeiGaCVza45ljA09vkF71Bl73WsHJEYFrLwTSC4FAeiGQXgikV4NhXvuqUVi2dellpOidWqmK8tqdmxPeruX7Nf5iP7qOz9c2JKNN2Eij1qFXYbhnzf1ra1g3hV/xsUk/tL7dBmS0kzqOdi1DL9O1iv7HYXKlqqtRHWxWk9UznobVjMma6atxgclz7UCPm9TkjOcnyno1ReGmKV05btuqZIeUttQ+xQeeC8pBMBRZs5keN8aDMeMyfZfVFDvQ38pClytz/S30xlhMflu2LGkZMGSU0VZC0+9WfSixpP6NBHvG6d/vKPMd3y5AUp5NFuFXF7Z1PF0c35Ome77ZsdBJ9uy59Nb3Ftg9rNuYjS4txDUH9mQnj6WWhZ9uQcfnX4flxNX5bUus4ku//Wx71+QfPr8EXxqCBNnH7WnVBKd+8gQsxxY6j47Af/z0e1ceaWPtLUL6d9vg24lY25IIgbQVY229Rdsi2PPW5MmvMWvRVjy2ePWHRTjzlBscH96tCgGl8k0fvU7KIPuyQHcERshHUxiT8gCnNbBu9vaoo2yPUOMS3MNsnFEYC5Sz3I9qYR9j+l1P7pozZg6NGQNk6zEJrMd8e4579gO0m/bIadL+QdC4ikjjGt0Hxi47nl20LWDvLnNr0da3irZNZbQuMqoCmn0ztPmJFYDzWWOVUpXs2v2pkzen19KwQklxRF7r9hSPOOmQFLeSHJfKaM13L60kL5fIaDPu+jJaXiDaGv5QEdKHmbbWh4Wj10pDZLTVjZv/lU6nt18UW1Sp2uYJEndu+/5V307sgXABcE3sqjKugE3CzIurmjsXkeMG1x2MxWziSlhGS9+5nsJR+K7S/vZ4MYm2Di5OxwfxOkYLLe2pShXUC2LrxEXYJwFIe11SvCyN0Ps3MsN0D9WwSmFHbqPug71qaRlX0xYj+l1vjnV9bS0lDJvFZDIJHjPYWYA0DIaY7rhuV+53Fc/u85G22BUNeB9/AoVoSzOMKTIYa3jbSavQqzhC/hv5kvjC33+7kp8E+I2TGAKIz3+ZfuYKW0BNdrM9AbjNuHPczZWU5bqkPyYUmnu679Sq5nJdx/OBkFtijwb40Q0Ab9jSwixp5VblHqHMTSpUt2vZn5v17B52JDeq/R3RbH47l2jrVVvuIqY3vIA8apG1VwvA7MscrGd9biJr4Nqr/NrrnahzNJyFelb36NfDiy+k1zudXg0F3gyNMtpmdC0C8IYcBNILgfRCIJBeiGYCl/Z45tjA0xukF84H9QZmo0Xgdw2B9EIgkF4IpBcC6dVsmDXt2qiLGd6Ft5/WC01WCqXGN2z4T5Xzjf3vyIZrezRSm7G9EJSLhogtqbdcoKKsdFcing9toVIo/Fz71h+91tC8Ohuv7ebIkPVBK1QuGkqzejcgo7XyONq1zuSY0pky1mUZZodjsjbMhK+K3qPQ8pThKVuH43JsmClaw3louT2th/1xNfmJQC3bpSq2cUwOctwCU8PSm0l7VEVkqBX5cgn6fyIF5aw+XRX1pkKxeUpeErPIRpuJyWoXeZEUrQckCWW0LbT24nlqv6tNLAIcUAvqAVK2lJ113Cwth1xWfZ7ZHZgt5G5jqWGfn3NmRB5aYS+GkTToLyUfBGiXCi+0s6rPGEvPnn0GoHtS5KCFdnma3jE/P+TM/glz+VORL5eMUudC5TwH7ZSoN9QWj5fi8SmN1/nhVwpU5P1Mwnn14wDyQ8ij1qHXOFPGvjjaR5Ys6giMUjXOhKHdxMuhaIz8J7NTJdD49PcF8u42XibsfRRuvJxnottOBXi223FjgCzJ7u728syqo8YbdBkwABpfqv2zyJfL89IG5RSjobvmvbbGPSUvvN8QuWrtAbBI2XOuvf8kwJtfRB5VQJNvhg7lm/WVqZIbEb76WtVA2RrkoY3aR6oJZZwVLucZv6jGlSpfe7/+ZZ6h1u11ab5cEHlp/fJIbGIjFFu4leGjLN2t21XY1jHD6/FXYnipZ1m/9p0hMsyaYJaE4HpaVaFshYja1bc3w9WsyjjLXBzvMgO1SS7fKBJEJldmRK5amns2KC8TYUlsvV6rR9pk6iQtvE1z2pp4sthy173a+7PHmFq2Px/d0QP7eEneBUNjn/IJ/g58+3M8Z23GBOkCFeY6++BC9DRSybHssvTdBdhNXu7L7afrpvMuFHmuWoITWrg8UGhneDbai6WxLcBFhZ96c8UvzWn7SYCLJ5BHrUavn9q7f0kzvipOyR1SbbLzBh9Zk8riFZZT9lCXvPgzvprn9nM8Z62yA7RHrpDtoiPfGb08lnuPbHN65e5U6OPiDokMtQmY6/iEOOqH1HD5n+/wucneWbeXxvaaegfX1cY/sIM+hqVDlwfvBziMS/sWWXtVtTprGsx3XZU2X4vbeQmz0VZYe7UcveRCExvT67FsWumOyGiRXsstrHNsJrvqI6lui160X8YpMbTCxi6o84CIXdAKS3sE0guBQHohkF4IXNojNn0yil2AMlqcDxoIlNEi8LuGQHohEEgvBNILgfS6ZjCb4LE5P0Qr08uNK3Jn8NGWZn1914bT1Fby0Fdq8quQjfZRA2m0FejVKWen23ZX3H3zhtPUVvAw7WJNfgKluw4t4mi3Fei1PGoYc3dDSDVrxpWSHLFaDlzNK6dDyRnVs0/Zcsz1M9ymulQhh011KcSdlKtn+MDTL0s1+ZE4YjwbbY+mHNdB5LQ9KF9AHm0BerXv0XvhJJm7XvNUs/qs8x0ynD2sdHYJcevii/A7kldO8daUb987rbQTH8VR6VbblJDDwnJ2NgmwW556mbs4cm1+8Mil2C72Zv5V59ACwEKsYH4c4O2PIY+2AL3eWirMaj0A6kHQuDBIk+DTBYB/DXLEnvsLeEj2yinuNHx7yxhViM8ojFD1a6CInTBo6tjCmPEw3156szY/eNiY4cq4/AB8+jDNaWvYpwFszEZbCS12r72517HXzBFr9jnHTnvlIFSzvr2npV2ltCX/JBdC6Whr8Qtlo+0tFm9Og7lzGTovo4y2dJGjt2RnKCYYs/evnSPWONGVCStsPasCeHrZMspcPk6bIFy8m+M36gdZz6Jz5TJ9CpNhZ2N34XWMLTI55ve6ZvJZniOWT45+jtheP0ds542yXy7g2evQr/A8tkL9ej48ayl74Svn+BrvYm1+sA8u2nx6nbEfIS/HbKPtKVIsI4+2AL0sK7FjieWIlRe5MP8NkSM2f9cZL0fsfedG/HIBz96QafbYSUPJvyH4kwjVPuEoj3NhkHy4Nj+Iabfz27nOdvQ9Tl6+akgLcYCihDzaGmuvzWB9Aa5hs8GnRD1btV8FDB+ZQhlthbXXdUSvdQS4Kw88te0Kp5XuztfkVx6Jy+HnhyK9rlN6tcgMj12A2Wib0LUIwBtyEEgvBNILgUB6IZoJXNrjmWMDT2+QXjgf1Bsoo0Xgdw2B9EIgkF4IpBcC6fXOAN6BivRqAGxNitGbu3ZWUOBWkNIikF5VoFc33Vf07Jo5cCnS2FVIrxoGL1WDAXUH19Hqg7LNstkmeKZbZjGsiYy0PZpMdZEZWVZ7sOOQXtWgMEb+G1O5Znf5h2c7AbpnCyyv7T9MMYsDl0Z4RtoFsxBbBBhMFIbmseMqAH8UiuAwvWveEMqfcYPeh+9IYNI0e3fyG+otAxSxSgOTyiCdzP48dhyOXtWAZR/1zho5n25JpVIr/hZ9uZWfWyYTdLqchMG+LHYc0qsaSHvJfxc+H2GcL+plcMHkz5nYCfLPyUv3wrR2H3Yc0qsa/CafAfsjT3pJlCmULOjxwCIJ2g/Ym+Vfj9D08WrGyGaw45Be1aBv6MNS99AMGcb81LS598r5kNJsTu2dYG9in2FpbBNHleRZ7LgKQCFanYE6x1Z9hAkCL0wg1vvuYhcgvRoGXGvg0h6B9EIgvRAIpBcCl/bXBVBGizLaRqLtHd8DKzg5InDthUB6IRBILwTSC4H0qhZmnWwQ1we9UqmUHMsylVVUJppaUzdqK/9Stjyc07WS+861o9uEWlW42o+W2WconZuosjSohI00qmr0Sqen5c/wd6V2a+hGk/EHy5aHc7pWcj/U4MMz9XItLMxe2USdpccyqeMYXOXkaMye9cerpCZnANyEbIiCLpW+HdaULv4FNmOyZkLq8O8xj4xM9aU9qnLcCOd0dTWqRaXuBsv2molJVH2aSqpShllkJEXoUHtUWfjSdkxNEVd/iSdph0bCFKxJjfgw7aobl3gJrcuPL+ZlqiW4oByk2Wap1bCXbVZJ3fJHNPesxnPPQkpXVD2jKMS3V2MvIg+tq9IIQvX1xjSejVbYGbKkZchYuBd5VOXaS48F7y/NkZ7sbp/2Mk8vTyUWAA6oWXHHnK4UtF3g5W49Nk3VpvNDLE9rkNNVVxYES4pZZRfA0ZxL1aewMpUeZL6pDmfoKjOYHyowX97Oru9ml0TDuaxG6ui2CvJXyNY/XiI+BerTLrlyu1eX55d6zcn5v0p87MeUFdNSd6g8S1vVFUfbxeIkRM7GnI9k48T3atyZpZpYnodWVztuitTn/DbB3wm7+ZhrHgX4MaYLrYpeZPH1+8EV/XFDGwC4e8yYEAUThnkLgDpqjPNtdRRGgp6dNEbv5nlaiVGQ07UwJgmVac4YJdZ5DWgtpLIBnphMKWT281yzni9vx73TyHlTnEHzxDoSWI8B07PK3OeBMRh9IKhL+B0ETfWCumc/i2zMCcrHjHDsNE7LMG8aZ775GdB4TfTFHZs5Halv3LjM3wm7bxVtmxzcfqRXJYSlHDQ1WOZoPpqMVXFKsrN6uVzD2VnFBrF1e4sDTrokp6v3nloPH12iiVwDA7ersK1jhhpFfVe3A37yWLfLbSM+oTyyQXwhsyDxbNRdGAe5Z71/bk/xSCR68HPWRo5X2A1/qAjpwywGHxb+5rhSWcoxsLz62kF05brNL6D5W9tK7JIrp/89Yh4IBl2Wy/UP2uSrEQNp4W3tAD9HiPgG7QDPE3su0LNKC9PaPA9g1cFFZa9cdW1+qrS8fO7ZJMy8WBp6yK/XO15hd3BxOj6IV1c2svYqTS1H1q27o9ch+mE3143S/K2BOc/pWpzZ/0jk05H2umJq+Qr0k/XyUvtIe+QTVDPGS2f44izwFe2It7tZwlfV9fWs1IcszPL7oH/V8x2CXLZ09NKY+97OkvKS2D0Uh+zuUE39PccifovwPiVspxnGFFlMaHjbSZVrL7kwUmIw7irR3rMc5RT3muxWnMngpFMukLXSHM/TSnGij/7/GycxxLfvUB6yAM4s9IXUDsQm8bz8DL9OEPKl7RTUU+LtKcUh679c1/G8OPFIPH8H9TEdubBq6Ji8VbnHv+7woxvIf9uPF79aUk5il/OTq3pj7um+U6EIPnH1VMRvRLMnwnZjttyVALjhBeRRFWuvqvHE5xZXX3Nc74lqqZofuVa7J5h9mYOpBj/rrSQbLa69VjaTLrQz37btZwdXFa+T0zW6/t0YavckY2phft3INolHj0ey0SK9VjAbbcOAN0NjNtpmdC0C8IYcBNILgfRCIJBeiGYCl/Z45tjA0xukV72B171QRovAtRcC6YVAIL0QSC8E0qsBMK9xO+Y1igfpVRmpVErRejYsus3IqyWs9zbpYEU7+ooXZ4X27y1/BJVktPgrdiNGr3Q6q/FMhhsR3Q6eXS1hdZp0sLwdM19cp31nzSMo3WXlcbRryORomP44IJSnwzG5SxQkj/FcrorOv+5unKpZU4f/lm4QO22YDwRcbturyU8ESllamS38pQTXeWViskLqtiVFyzAF6zHyMhyXY8NU1S9rNt9Hx1NdVo0Mj4fvT+lUYZviA0+/JHlx8vZouWhnmGp3hQDYi5H58kNQRSZaEova5bUnSf3Io4asvfTgPs3l7OxdVGM77UuNnmW5XNs9MWy7XHih3RPdHlAL6oFgOEiD/VLyQaqLpTa0sjPGDu4/6cpcXfHhVwo0ifpfJpxXnwFY+Il76hukntlC7jaqZy2YZIrqJPuoDOkb01b+Izwevh+WqMJWtF2Q/TjbrcLpblYu2rlVmbBLYyS+It3sd6de9mOhdBbtyQ8hj+pPLyq6DbYmDK0AoI742tdxY2CAzDNDngpXHYVOxbNWR2BUDVdWuPFyntvQ4pwxcEj4d4PJ5y57AKxbAJ5z7f0nCTEGbfs0cZBAc6hikelZFZcrct9vaDeN83j4fqGw5bjpTT9OsvsIr120c9NYX740RuLLBb9wyBjIh2MR7b35ReRRBdR+MzRVSPTedTKqsZVcKKvChTKi20DFGlbbejZRUSxdMu1ZWjrkq27NdxcheZntzrgw/KElmJfA1Z1tQl0bcs+4UV0sjdGLEzxpbUR8G4QUUtpCSLUrtMCivYjOAO+1X0tGuzFcfqqkYLsJbulJ/jB/cy6seX3dV7EGktxSG17ui1jf1SbTkwJp4e0YmauMxekE2Xyd7HapnjUb+xzZN8/2hSD2Rwds048zUOaKds6Hml+ttHW96I5wLbBoz0RGNWjttb2kQO6HnkiBcgFuO8enHw0u+Kdo9kUmgD1v0yUT7DNButCrlthw/5z3VJUVielvVdt48ZNMwXqJ1uMyjatmG21P+vtCEPsF9jF2tF/041Rd+HmMlYt2TuzLqp6dpJWKdJNwkU/vK5fDsVw8gTxqxNpLceZKyiacwWiNuTtlUVDske/0rwgUb1cKFsBscgdhBTy3A7RHrlglNtz/PXKeS7NnP7CDrLmgQ5cH7wd49YNykpRbSWWRDGLxj0sLc/6+8EUDvl/gOZZi9u8P+3HmuuSH46xctPPZxT2WZ5fuVpzo3VuvqXfwlWX8o+FYDuPSvv5rr+qHuMJCSx2yufOKVM/63M5LKKOtsPZqNL1W1BVpVmqtw9fd+boeYnd4vYj0CtOr0XertjlQaDF21ft+5bbo2cgKTokB8Gboeg+N2AV1O3NEIJBeCKQXAumFQCC9EEgvBNILgUB6IZBe7whY19i/tSpAeiFw9EIgvRCIEuCDx1ts7XU9AB883oS+rZGem/26t0AFODkicO2FQHohELi0R1yL8xxc2jfi3FFnL3r1y2Tfh71uyDVYTuu1tR0sx/WqI+C7gqgrNYr0qju7eCezv1Wzy/tgdLFVvWvkhLWWtgN3C6qNwCo50oqN4tqrhS5m1H5JwNLr9r2oa2s4ejV4IKtlXq3B1Sq94LbxtvWqI9CrPmCkV6MGJIv+tao+c/LmRvK6UVfwPWtse1U9NUVQzgfp1cgJT6xMNjhH1uCqb7rtzUZQ3gfXXq0xN1qbnNo2Py/rm1/NrfZBerUQE2v/ObxeP6TX+wd5vKxaf6qErxJU172hq04bdY02uokK9I0EX+66VxkfC+mFaOA3DSdHRAOB9EIgvRBILwQC6YVAeiGuC4R+FEKNC6JO0MvQC6+AIeoDCydHBK69EEgvBALphUB6Ia4vtK+98t9655QYe8vTq3RMW97CR1TcSrGXpLva+umJcHJEIL0Q1zu9rCr3rrKzrKD0Gv3wZJVt3NoSx+PHXimkVu76egnR1nscwVZbq7bg8ehbsOs3Pjlalvgm+d8Mi/0Re8LfOG5plXyThFlg3dRhzGs8fDTei9XSx8Pbgkj8rd71Gx69yj2JwNKje8Lb3lMtfIFl9MEXTeeXHvxdHUwQa2seD20n0nird32Nk6NuiT8l466+akxeNTbr13S81su2rUdfW+t4rJKeXx1g63Z9HR8CoIceUrV+d+lWS6zE1lj3tsrxVKGwbdmub69vP9BvzzqPJrBCDym79vzSIzFt2eNp1VBrve6ls+eo6LVcuQidFDSt961VE4e1zlWLVj0eazMXjZre9e0bPDC98sga7OG8i1rqlr+T72nq5FjSWjgY+k7E1PLHUzbOVu760EMAgm93qXZ7eSv9LFz6m+NWir30N0d9vYtZLXoceoUPA9HanxtssbsokF5bCVvuBp3y9Frewh9BcQvHvnK9fR/ar4svCcbeosAbchBILwTSC4FAeiGQXgikFwKxNsIXJvAJTIjG0Qufv4TAyRGB9EIgkF4IpBcC6YVAIL0QSC8EAoFYH/8Pz/OuBd8JG50AAAAASUVORK5CYII=</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-11-03 14:58:52 +0000" MODIFIED_BY="Anupa Shah">
<APPENDIX ID="APP-01" MODIFIED="2011-11-03 14:51:14 +0000" MODIFIED_BY="Anupa Shah" NO="1">
<TITLE MODIFIED="2011-11-03 14:51:14 +0000" MODIFIED_BY="Anupa Shah">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-11 19:54:59 +0100" MODIFIED_BY="Anupa Shah">
<P>#1 MeSH descriptor Entropion<BR/>#2 entropion or entropium<BR/>#3 (eyelid* or eye lid*) and (inver* or malposition*)<BR/>#4 (#1 OR #2 OR #3)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-11-03 14:55:16 +0000" MODIFIED_BY="Anupa Shah" NO="2">
<TITLE MODIFIED="2011-11-03 14:51:39 +0000" MODIFIED_BY="Anupa Shah">MEDLINE (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-03 14:55:16 +0000" MODIFIED_BY="Anupa Shah">
<P>1. randomized controlled trial.pt.<BR/>2. (randomized or randomised).ab,ti.<BR/>3. placebo.ab,ti.<BR/>4. dt.fs.<BR/>5. randomly.ab,ti.<BR/>6. trial.ab,ti.<BR/>7. groups.ab,ti.<BR/>8. or/1-7<BR/>9. exp animals/<BR/>10. exp humans/<BR/>11. 9 not (9 and 10)<BR/>12. 8 not 11<BR/>13. entropion/<BR/>14. (entropion$ or entropium).tw.<BR/>15. ((eyelid$ or eye lid$) and (inver$ or malposition$)).tw.<BR/>16. or/13-15<BR/>17. 12 and 16</P>
<P>The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (<LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-11-03 14:54:04 +0000" MODIFIED_BY="Anupa Shah" NO="3">
<TITLE MODIFIED="2011-11-03 14:52:07 +0000" MODIFIED_BY="Anupa Shah">EMBASE (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-03 14:54:04 +0000" MODIFIED_BY="Anupa Shah">
<P>1. exp randomized controlled trial/<BR/>2. exp randomization/<BR/>3. exp double blind procedure/<BR/>4. exp single blind procedure/<BR/>5. random$.tw.<BR/>6. or/1-5<BR/>7. (animal or animal experiment).sh.<BR/>8. human.sh.<BR/>9. 7 and 8<BR/>10. 7 not 9<BR/>11. 6 not 10<BR/>12. exp clinical trial/<BR/>13. (clin$ adj3 trial$).tw.<BR/>14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.<BR/>15. exp placebo/<BR/>16. placebo$.tw.<BR/>17. random$.tw.<BR/>18. exp experimental design/<BR/>19. exp crossover procedure/<BR/>20. exp control group/<BR/>21. exp latin square design/<BR/>22. or/12-21<BR/>23. 22 not 10<BR/>24. 23 not 11<BR/>25. exp comparative study/<BR/>26. exp evaluation/<BR/>27. exp prospective study/<BR/>28. (control$ or prospectiv$ or volunteer$).tw.<BR/>29. or/25-28<BR/>30. 29 not 10<BR/>31. 30 not (11 or 23)<BR/>32. 11 or 24 or 31<BR/>33. entropion/<BR/>34. (entropion$ or entropium).tw.<BR/>35. ((eyelid$ or eye lid$) and (inver$ or malposition$)).tw.<BR/>36. or/33-35<BR/>37. 32 and 36</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2011-11-03 14:58:10 +0000" MODIFIED_BY="Anupa Shah" NO="4">
<TITLE MODIFIED="2011-11-03 14:52:55 +0000" MODIFIED_BY="Anupa Shah">metaRegister of Controlled Trials search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-03 14:58:10 +0000" MODIFIED_BY="Anupa Shah">
<P>entropion</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2011-11-03 14:53:21 +0000" MODIFIED_BY="Anupa Shah" NO="5">
<TITLE MODIFIED="2011-11-03 14:53:21 +0000" MODIFIED_BY="Anupa Shah">ClinicalTrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-11 19:54:53 +0100" MODIFIED_BY="Anupa Shah">
<P>entropion</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2011-11-03 14:58:52 +0000" MODIFIED_BY=" Iris Gordon" NO="6">
<TITLE MODIFIED="2011-11-03 14:58:45 +0000" MODIFIED_BY=" Iris Gordon">ICTRP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-03 14:58:52 +0000" MODIFIED_BY=" Iris Gordon">
<P>entropion</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 study included in the review and 1 ongoing study awaiting data&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 full-text articles assessed for eligibility   &lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;111 records screened by the authors&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;267 records screened by the Trials Search Co-ordinator (TSC)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;267 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;299 records identified through electronic database searching&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;156 records excluded after initial screening by the TSC&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;108 records excluded by the authors as not relevant&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 full-text article excluded, with reasons&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>